Enliven Therapeutics ELVN Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's other income, net (note 6)?
- Enliven Therapeutics (ELVN) reported other income, net (note 6) of $0 in Q1 2026.
- How has Enliven Therapeutics's other income, net (note 6) changed year-over-year?
- Enliven Therapeutics's other income, net (note 6) increased by 100.0% year-over-year, from -$47K to $0.
- What is the long-term trend for Enliven Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Enliven Therapeutics's other income, net (note 6) has grown at a -27.3% compound annual growth rate (CAGR), from -$175K to -$49K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.